coronary

Felix Zijlstra Felix Zijlstra, University Medical Center Groningen, The Netherlands Thrombus aspiration before percutaneous coronary intervention for acute myocardial infarction has multiple benefits,

George Sopko

Philip Barter Gordon Tomaselli REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida N Engl J Med 2007;357 PHILIP BA

Gordon Tomaselli Daniel Jones REFERENCE: Late Breaking Clinical Trials 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida GORDON TOMASELLI, Johns Hopkins Universit

Edmond Cronin REFERENCE: Abstract 3506, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria EDMOND CRONIN, Cork University Hospital Study data that support banning smoking in

David Wood REFERENCE: European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria; Abstract 316 DAVID WOOD, Charing Cross Hospital, London Among 8000 coronary patients in 9 European

HARVEY WHITE, Auckland City Hospital REFERENCE: ACC 2007 & N Engl J Med 356: March 2007 The finding from the COURAGE trial: that angioplasty adds no benefits to optimal medical therapy alone for

Patrick Serruys Spencer King PATRICK SERRUYS, Erasmus University, Rotterdam COMMENT: SPENCER KING, Piedmont Hospital, Atlanta REFERENCE: Abstract 2402-3, American College of Cardiology New Orleans Six

DAVID MOLITERNO, University of Kentucky, Lexington REFERENCE: American College of Cardiolgy New Orleans, March 24th Late Breaking Trials An oral thrombin receptor antagonist, SCH 530348 has proved saf

NILESH SAMANI, Glenfield Hospital, Leicester REFERENCE: Lancet 2007; 369:107 A new genetic test could help predict which individuals will develop coronary heart disease among those with similar conven

Thorsten Dill Simon Hoerstrup Harvey White REPAIR-AMI Study: Bone Marrow Cells Improve Ejection Fraction, Reduce Remodeling REFERENCE: Abstract: 3770 THORSTEN DILL, Kerckhoff-Klinik, Bad Nauheim Proge

Shamir Mehta Keith Fox Petr Widimsky Gerrit Veen OASIS 5 & 6: Fondaparinux Anticoagulation: Benefit on Mortality, Events and Bleeding in Acute Coronary Syndromes and ST-Elevation Myocardial Infarc

David Wood Magnus Ohman Kenneth Morgan Philip Poole-Wilson EUROACTION Study: Nurse-Led Teams Succeed in Modifying Lifestyle to Reduce Coronary Risks REFERENCE: Abstract 986; Hot Line 1 Session David W

Anthony Wierzbicki Gabriel Steg David Paquette Add HDL-Raising Therapy to Maximise Lipid Treatment REFERENCE: Abstract 53, Page 85 Anthony Wierzbicki, St Thomas’s Hospital, London The idea of ad

Annual Meeting of the American College of Cardiology March 11-14, 2006, Atlanta: Single Agent Bivalirudin Better for Acute Coronary Syndromes; Ultrafiltration vs. Diuretics in Heart Failure; Salt Subs

Annual Meeting of the American College of Cardiology March 11-14, 2006, Atlanta: Atheroma Reversal, Statins for Acute Coronary Syndromes, Targeting Dual Antiplatelet Therapy, Clopidogrel and Drug Elut

Anthony Bavry, The Cleveland ClinIc, OH American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta. Abstract Number: 821-5 All cause mortality can be reduced by 25 per cent if

Antonio Abbate, Medical College of Virginia, Richmond American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta. Abstract Number: 2912-74 Even though drug eluting stents have

Peter Smith, Duke University Medical Center, Durham, NC Late Breaking Clinical Trials, ACC Atlanta 2006, Sunday 12th March 2006 The drug pexelizumab, targeting inflammation, reduced the risk of death

Deepak Bhatt, Cleveland Clinic, Ohio American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta The idea of adding clopidogrel anti-platelet therapy to standard aspirin therap

Gregg Stone, Columbia University Medical Center, New York American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta A superiority for the anti-clotting drug bivalirudin for t

Michael Lincoff, Cleveland Clilnic, Cleveland Ohio American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta The full picture of how bivalirudin is emerging as a treatment wi

Anthony H. Gershlick, Leicester University Abstract: N Engl J Med 2005; 353:2758 If your patient with myocardial infarction has been treated with thrombolysis as primary therapy, and if reperfusion is

Keith Fox Keith Fox, Royal Infirmary Edinburgh The RITA-3 trial – focussing on how to manage patients with acute coronary syndromes – reported 5-year data at this year’s ESC Congress

Caroline Daly The Euroheart survey has found significant differences in both diagnosis and treatment of heart disease in women as compared with men. Audio Medica asked Caroline Daly of London’s